[ESMO 2020] HLB 리보세라닙(아파티닙) 발표 자료 정리

ESMO 2020, 리보세라닙(아파티닙) 관련 발표는 oral session으로 3개 그 외 18개의 포스터 발표가 있다.

하나씩 듣고 읽어보는대로 업데이트하고자 한다.

 

ORALS

1. Mini Oral Session - Hematologic malignancies, 한국시간 9/18, 금 16:00부터 available

893MO - An open-label, single-center, phase II, single-arm trial of camrelizumab combined with apatinib in patients with relapsed or refractory peripheral T-cell lymphoma

2. Mini Oral Session - NETs and endocrine tumours, 한국시간 9/18, 금 16:00부터 available
LBA89 - A randomized multicentered phase III study to evaluate apatinib in subjects with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer
 
3. Science Weekend - Proffered paper session, 한국시간 9/20, 일 22:09~22:21 live, 23:05부터 on demand available

LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-ine treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): a multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)

Li Zhang, Guangzhou, China

 

POSTERS

1. Poster ID 15P

Study on the mechanism of apatinib reversing tamoxifen resistance in breast cancer

Qingxia Li, Shijiazhuang, China

 

2. Poster ID 38P

Study on human plasma concentration and serosal permeation of oral apatinib mesylate

Jian Shi, Shijiazhuang, China

 

3. Poster ID 270P

Apatinib added to taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial

Yunjiang Liu, Shijiazhuang, China

 

4. Poster ID 442P

Camrelizumab combined with apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer: One-arm exploratory clinical trial

Li Xiao, Xiamen, China

 

5. Poster ID 941P

Efficacy and safety of apatinib combined with capecitabine in patients with advanced nasopharyngeal carcinoma/

XiuYu Cai, Guangzhou, China

 

6. Poster ID 983P

Camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (RESCUE): An open-label, multi-center, phase II trial

Jianming Xu, Beijing, China

 

7. Poster ID 1267P

Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC

Guanghui Gao, Shanghai, China

 

8. Poster ID 1366P

Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance (date updated)

Ruifen Tian, Taiyuan, China

 

9. Poster ID 1427P

A phase II study of neoadjuvant concurrent chemoradiotherapy with apatinib for HER-2 negative Siewert type II and III adenocarcinoma of esophagogastric junction

Qun Zhao, Shijiazhuang, China

 

10. Poster ID 1428P

Apatinib combined with docetaxel in second-line treatment of advanced gastric cancer: A prospective clinical study (data updated)

Mudan Yang, Taiyuan, China

 

11. Poster ID 1431P

Study on the safety and efficacy of apatinib combined with concurrent chemoradiotherapy in the treatment of non-operative oesophageal cancer

Jingping Yu, Changzhou, China

 

12. Poster ID 1434P

A prospective, multicenter, non-randomized, controlled trial of apatinib plus perioperative chemotherapy with FLOT protocol and surgery for the treatment of stage III gastric cancer

Jun Zhang, Shenyang, China

 

13. Poster ID 1452P

Phase I study of apatinib plus POF (paclitaxel plus FOLFOX) in patients (pts) with treatment-naïve advanced gastric cancer (TNAGC)

Rongbo Lin, Fuzhou, China

 

14. Poster ID 1455P

A single-arm, open-label, prospective, multicenter study of apatinib combined with chemotherapy as second-line therapy in patients with advanced gastric cancer

Jifeng Feng, Nanjing, China

 

15. Poster ID 1503TiP

A prospective study of apatinib in combination with neoadjuvant concurrent chemoradiotherapy for locally advanced esophageal squamous cell carcinoma

Jun Wang, Shijiazhuang, China

 

16. Poster ID 1646P

Apatinib for treatment of inoperable metastatic or locally advanced chondrosarcoma: What we can learn about the biological behavior of chondrosarcoma from a multicenter study

Lu Xie, Beijing, China

 

17. Poster ID 1804P

The efficacy of apatinib plus topotecan as laterline therapy for advanced small cell lung cancer

Haifeng Qin, Beijing, China

 

18. Poster ID 1805P

Apatinib combined with irinotecan in the treatment of small cell lung cancer: A phase II, single-arm, prospective study

Yanbin Zhao, Harbin, China